Teva Launching "6 vs 12" Campaign On Follow-On Biologics
This article was originally published in The Pink Sheet Daily
Six-video series will profile patients struggling to pay for biologics in effort to make the case for brand exclusivity shorter than 12 years.
You may also be interested in...
PERTH, Australia - Australia's Minister of Health Nicola Roxon requested advice from the Pharmaceutical Benefits Advisory Committee on the potential benefits of adding Alexion's Soliris (eculizumab) to the government's Life Saving Drugs Program (LSDP)
Lopsided committee vote suggests that lengthy exclusivity is here to stay, which means that big pharma can get more comfortably behind the broader reform effort.
At a public town hall meeting in North Carolina, the President suggests late fall, lower exclusivity will feature in the conclusion of the health care debate.